Elanco动物保健公司预计2025年第一季度收入在11.55亿美元至11.8亿美元之间，相比市场共识预期的12.11亿美元有所下降，调整后每股收益预计在0.29美元至0.34美元之间，高于市场共识的0.30美元。公司预计第一季度收入将受到约4000万美元的外汇不利影响，剔除外汇不利影响和水产剥离，预计收入将增长2%至4%。此外，公司预计运营费用同比将上升6%至8%，主要由于全球创新产品组合的战略投资。第一季度调整后的息税折旧摊销前利润（EBITDA）预计将受到约1500万美元的外汇影响。公司预计第一季度调整后的有效税率将在中个位数范围，全年预期税率为21%至22%。

以上内容来自Benzinga Earnings专栏，原文如下：

In the first quarter, the company expects a headwind to revenue of approximately $40 million from the unfavorable impact of foreign exchange rates compared to prior year. Excluding the unfavorable impact of foreign exchange rates and the aqua divestiture, the company expects 2% to 4% revenue growth.

The company expects operating expenses up 6% to 8% year over year in constant currency with strategic investment in the global launches of the innovation portfolio. First quarter adjusted EBITDA includes an expected foreign exchange rate impact of approximately $15 million compared to prior year.

The company expects first quarter adjusted effective tax rate to be in the mid-single digit range as a result of a discrete tax item that will also benefit the full-year expected tax rate of 21% to 22%.